{"Abstract": [0], "The": [1, 57], "PI3K/AKT/mTOR": [2], "(PAM)": [3], "signaling": [4, 45, 65, 121, 162, 167], "pathway": [5, 66, 84, 122], "is": [6, 36, 60, 71], "a": [7, 148], "highly": [8, 37], "conserved": [9], "signal": [10, 50], "transduction": [11, 51], "network": [12], "in": [13, 32, 67, 74, 108, 118, 123, 138, 144, 168], "eukaryotic": [14], "cells": [15], "that": [16], "promotes": [17], "cell": [18, 20, 23], "survival,": [19], "growth,": [21], "and": [22, 47, 70, 95, 105, 125, 132, 137, 170], "cycle": [24], "progression.": [25], "Growth": [26], "factor": [27], "signalling": [28], "to": [29, 54, 76, 160], "transcription": [30], "factors": [31], "the": [33, 61, 115, 119, 127, 155], "PAM": [34, 58, 120, 161, 166], "axis": [35, 59], "regulated": [38], "by": [39], "multiple": [40], "cross-interactions": [41], "with": [42, 140], "several": [43], "other": [44, 141], "pathways,": [46], "dysregulation": [48], "of": [49, 80, 82, 88, 91, 93, 97, 102, 129, 158], "can": [52], "predispose": [53], "cancer": [55, 69], "development.": [56], "most": [62], "frequently": [63], "activated": [64], "human": [68], "often": [72], "implicated": [73], "resistance": [75, 104, 159], "anticancer": [77], "therapies.": [78], "Dysfunction": [79], "components": [81], "this": [83, 111], "such": [85], "as": [86, 135, 147], "hyperactivity": [87], "PI3K,": [89, 130], "loss": [90], "function": [92], "PTEN,": [94], "gain-of-function": [96], "AKT,": [98], "are": [99, 172], "notorious": [100], "drivers": [101], "treatment": [103, 152], "disease": [106], "progression": [107], "cancer.": [109], "In": [110], "review": [112], "we": [113], "highlight": [114], "major": [116, 156], "dysregulations": [117], "cancer,": [124], "discuss": [126], "results": [128], "AKT": [131], "mTOR": [133], "inhibitors": [134], "monotherapy": [136], "co-administation": [139], "antineoplastic": [142], "agents": [143], "clinical": [145], "trials": [146], "strategy": [149], "for": [150], "overcoming": [151], "resistance.": [153], "Finally,": [154], "mechanisms": [157], "targeted": [163], "therapies,": [164], "including": [165], "immunology": [169], "immunotherapies": [171], "also": [173], "discussed.": [174]}